Centennial Campus Collaboration May Yield Benefit For Flu Sufferers
FOR IMMEDIATE RELEASE
Can a cancer drug reduce the sometimes severe symptoms of various forms of influenza, possibly even the dreaded avian flu? How does a company focused on cancer research collaborate with an immunologist interested in controlling the effects of inflammation in diseases?
The partnerships spawned due to the existence of NC State’s Centennial Campus hold the answers to these questions.
Dr. Scott Laster, NC State professor of microbiology, and the research and development arm of Erimos Pharmaceuticals – a Houston, Texas, company focused primarily on the discovery, development and commercialization of cancer drugs – recently filed a joint provisional patent for use of a developmental Erimos product to reduce the often fatal complications of multiple flu strains, including avian flu. The product – a small molecule named EM-1421 – is currently in clinical trials for treatment of malignant tumors. More... |
